Pradžia › Ūmi bifeninė leukemija
Ūmi bifeninė leukemija klinikiniai tyrimai JAV ieško dalyvių
37 tyrimai dėl Ūmi bifeninė leukemija ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Seattle, WA15 tyrimai
- Houston, TX11 tyrimai
- New York City, NY10 tyrimai
- Atlanta, GA9 tyrimai
- Durham, NC8 tyrimai
- Memphis, TN7 tyrimai
- Chicago, IL7 tyrimai
- Charlotte, NC6 tyrimai
- Aurora, CO6 tyrimai
- Baldwin Park, CA6 tyrimai
- Portland, OR6 tyrimai
- Los Angeles, CA6 tyrimai
- Philadelphia, PA6 tyrimai
- Dallas, TX6 tyrimai
- San Diego, CA5 tyrimai
- San Francisco, CA5 tyrimai
- Boston, MA5 tyrimai
- Clifton, NJ5 tyrimai
- Tampa, FL5 tyrimai
- Nashville, TN5 tyrimai
- Greenburgh, NY5 tyrimai
- Columbus, OH5 tyrimai
- Cincinnati, OH5 tyrimai
- Fort Worth, TX5 tyrimai
- Minneapolis, MN5 tyrimai
- Mountain View, CA4 tyrimai
- Jacksonville, FL4 tyrimai
- Denver, CO4 tyrimai
- Milwaukee, WI4 tyrimai
- Greenville, NC4 tyrimai
- St. Louis, MO4 tyrimai
- Kansas City, MO4 tyrimai
- Akron, OH4 tyrimai
- Washington, DC4 tyrimai
- Baltimore, MD4 tyrimai
- Omaha, NE4 tyrimai
- Cleveland, OH4 tyrimai
- Ann Arbor, MI4 tyrimai
- Edison, NJ4 tyrimai
- Orange, CA4 tyrimai
Pagal valstiją
- Aidahas3 tyrimai
- Ajova4 tyrimai
- Alabama3 tyrimai
- Aliaska3 tyrimai
- Arizona3 tyrimai
- Arkansas3 tyrimai
- Delaveras3 tyrimai
- Džordžija9 tyrimai
- Florida9 tyrimai
- Havajai3 tyrimai
- Ilinoisas7 tyrimai
- Indianas4 tyrimai
- Kalifornija15 tyrimai
- Kentukis4 tyrimai
- Koloradas8 tyrimai
- Kolumbijos apskritis4 tyrimai
- Konektikutas3 tyrimai
- Luiziana4 tyrimai
- Masčusetsas5 tyrimai
- Menas3 tyrimai
- Merilendas4 tyrimai
- Minesota6 tyrimai
- Misisipė3 tyrimai
- Misūris5 tyrimai
- Mičiganas4 tyrimai
- Naujoji Hampšyras3 tyrimai
- Nebraska4 tyrimai
- Nevada3 tyrimai
- New Jersey6 tyrimai
- New York11 tyrimai
- North Carolina11 tyrimai
- North Dakota3 tyrimai
- Ohio8 tyrimai
- Oklahoma5 tyrimai
- Oregon6 tyrimai
- Pennsylvania6 tyrimai
- Rhode Island3 tyrimai
- South Carolina3 tyrimai
- South Dakota3 tyrimai
- Tennessee10 tyrimai
- Texas13 tyrimai
- Utah3 tyrimai
- Virginia3 tyrimai
- Washington15 tyrimai
- West Virginia3 tyrimai
- Wisconsin5 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Renkami dalyviai1 fazė
Amžius nuo 12 iki 78 · Visoms lytims · Atnaujinta 2026-09-29 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT04375631Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07094750A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Renkami dalyviai1/2 fazė
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
Iki 50 metų · Visoms lytims · Atnaujinta 2026-09-01 · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Renkami dalyviai2 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-08-10 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06177067Personalized NK Cell Therapy in CBT
Renkami dalyviai2 fazė
Amžius nuo 15 iki 80 · Visoms lytims · Atnaujinta 2026-07-30 · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Renkami dalyviai2 fazė
6 Months – 65 Years · Visoms lytims · Atnaujinta 2026-07-22 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-20 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Renkami dalyviai4 fazė
Amžius nuo 1 iki 18 · Visoms lytims · Atnaujinta 2026-07-14 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-07 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
Renkami dalyviai2 fazė
Iki 75 metų · Visoms lytims · Atnaujinta 2026-07-06 · NCT05805605Registry of Older Patients With Cancer
Renkami dalyviaiStebimasis tyrimas
Amžius 65 ir vyresni · Visoms lytims · Atnaujinta 2026-06-29 · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-06-23 · NCT06551584211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-06-22 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-06-22 · NCT03670966A Study of Revumenib and Mezigdomide in People With Leukemia
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-06-22 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-06-12 · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
6 Months · Visoms lytims · Atnaujinta 2026-05-29 · NCT04195633Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.